Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Lilly to acquire Merida Biosciences for treatments

PRIVATEAug 31, 2026•8 days ago

Acquiring Company

Lilly

Acquired Company

Merida Biosciences

CambridgeBiotechnologyHealth CareBiotechnologyHealth CareTherapeutics

Description

Lilly has announced its acquisition of Merida Biosciences. This move aims to further enhance treatments for serious autoimmune and allergic diseases. Lilly intends to leverage Merida's expertise in the field. The acquisition reflects Lilly's commitment to innovative healthcare solutions.

Company Information

Company

Lilly

About

Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn. C-LLY

Don't miss Lilly's next move

Get an email the moment Lilly makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Lilly's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Merida Biosciences?

Merida Biosciences was acquired by Lilly. The deal was reported on August 31, 2026. Lilly unites caring with discovery to create medicines that make life better for people around the world. Lilly is privately held and operates in Biotechnology.

When did Lilly acquire Merida Biosciences?

Lilly's acquisition of Merida Biosciences was reported on August 31, 2026. Lilly has announced its acquisition of Merida Biosciences. This move aims to further enhance treatments for serious autoimmune and allergic diseases. Lilly intends to leverage Merida's expertise in the field. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Merida Biosciences do?

Merida Biosciences is a biotechnology company based in Cambridge, MA, focused on developing a new class of precision therapeutics. It is privately held, operating in Biotechnology, and is based in Cambridge.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.